Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis

被引:139
作者
Ajose, Olawale [2 ]
Mookerjee, Siddharth [3 ]
Mills, Edward J. [4 ]
Boulle, Andrew
Ford, Nathan [1 ,5 ]
机构
[1] Med Sans Frontieres, CH-1211 Geneva, Switzerland
[2] Clinton Hlth Access Initiat, Dar Es Salaam, Tanzania
[3] Univ London Imperial Coll Sci Technol & Med, Natl Ctr Infect Prevent & Management, London, England
[4] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada
[5] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa
关键词
protease inhibitors; second-line failure; viraemia; virological suppression; SUB-SAHARAN AFRICA; DRUG-RESISTANCE; ROLL-OUT; HIV; MORTALITY; EFFICACY; FAILURE; PROGRAM; COST; LOPINAVIR/RITONAVIR;
D O I
10.1097/QAD.0b013e328351f5b2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. Methods: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. Results: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. Conclusion: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:929 / 938
页数:10
相关论文
共 53 条
  • [11] Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa
    El-Khatib, Ziad
    Ekstrom, Anna Mia
    Ledwaba, Johanna
    Mohapi, Lerato
    Laher, Fatima
    Karstaedt, Alan
    Charalambous, Salome
    Petzold, Max
    KatzensteinG, David
    Morris, Lynn
    [J]. AIDS, 2010, 24 (11) : 1679 - 1687
  • [12] High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia
    Ferradini, Laurent
    Ouk, Vara
    Segeral, Olivier
    Nouhin, Janin
    Dulioust, Anne
    Hak, Chanroeurn
    Fournier, Isabelle
    Lerolle, Nathalie
    Ngin, Sopheak
    Mean, Chhi Vun
    Delfraissy, Jean-Francois
    Nerrienet, Eric
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2011, 14
  • [13] High Rates of Survival, Immune Reconstitution, and Virologic Suppression on Second-Line Antiretroviral Therapy in South Africa
    Fox, Matthew P.
    Ive, Prudence
    Long, Lawrence
    Maskew, Mhairi
    Sanne, Ian
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (04) : 500 - 506
  • [14] TRANSFORMATIONS RELATED TO THE ANGULAR AND THE SQUARE ROOT
    FREEMAN, MF
    TUKEY, JW
    [J]. ANNALS OF MATHEMATICAL STATISTICS, 1950, 21 (04): : 607 - 611
  • [15] The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
    Gilks, Charles F.
    Crowley, Siobhan
    Ekpini, Rene
    Gove, Sandy
    Perriens, Jos
    Souteyrand, Yves
    Sutherland, Don
    Vitoria, Marco
    Guerma, Teguest
    De Cock, Kevin
    [J]. LANCET, 2006, 368 (9534) : 505 - 510
  • [16] HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study
    Hamers, Raph L.
    Wallis, Carole L.
    Kityo, Cissy
    Siwale, Margaret
    Mandaliya, Kishor
    Conradie, Francesca
    Botes, Mariette E.
    Wellington, Maureen
    Osibogun, Akin
    Sigaloff, Kim C. E.
    Nankya, Immaculate
    Schuurman, Rob
    Wit, Ferdinand W.
    Stevens, Wendy S.
    van Vugt, Michele
    de Wit, Tobias F. Rinke
    [J]. LANCET INFECTIOUS DISEASES, 2011, 11 (10) : 750 - 759
  • [17] Hamers RL, 2011, LANCET INFECT D 1027
  • [18] CONVINCING EVIDENCE FROM CONTROLLED AND UNCONTROLLED STUDIES ON THE LIPID-LOWERING EFFECT OF A STATIN
    Higgins, Julian
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
  • [19] Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline*
    Hosseinipour, M. C.
    Kumwenda, J. J.
    Weigel, R.
    Brown, L. B.
    Mzinganjira, D.
    Mhango, B.
    Eron, J. J.
    Phiri, S.
    van Oosterhout, J. J.
    [J]. HIV MEDICINE, 2010, 11 (08) : 510 - 518
  • [20] Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi
    Jahn, Andreas
    Floyd, Sian
    Crampin, Amelia C.
    Mwaungulu, Frank
    Mvula, Hazzie
    Munthali, Fipson
    McGrath, Nuala
    Mwafilaso, Johnbosco
    Mwinuka, Venance
    Mangongo, Bernard
    Fine, Paul E. M.
    Zaba, Basia
    Glynn, Judith R.
    [J]. LANCET, 2008, 371 (9624) : 1603 - 1611